KMT2A and leukemia: The MLL-AF9 transformed cord blood cells used in this model display a unique sensitivity for ZOL such that strategies combining chemotherapy for MLL-rearranged AML leukemias with ZOL could target the leukemic stem cell population emerging in the hematopoietic niche in proximity to bone osteoclasts where ZOL is sequestered.